Identification of A‐kinase interacting protein 1 as a potential biomarker for risk and prognosis of acute myeloid leukemia

Abstract

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractBackground: This study aimed to investigate the correlation of A-kinase interacting protein 1 (AKIP1) expression with disease risk, clinical characteristics, and prognosis of acute myeloid leukemia (AML).Methods: 291 de novo AML patients and 97 controls were consecutively recruited, and bone marrow samples were collected to detect AKIP1 expression using quantitative polymerase chain reaction prior to initial treatment. Treatment response, eventfree survival (EFS), and overall survival (OS) in AML patients were evaluated. Results:A-kinase interacting protein 1 expression was higher in AML patients than that in controls; meanwhile, receiver operating characteristic curve displayed that AKIP1 was able to distinguish AML patients from controls (area under the curve:0.772, 95%CI: 0.720-0.823). Among AML patients, AKIP1 high expression was correlated with −7 or 7q−, monosomal karyotype, and worse risk stratification. Moreover, AKIP1 expression was negatively correlated with complete remission achievement, while no correlation of AKIP1 expression with hematopoietic stem cell transplantation achievement was observed. AKIP1 high expression was associated with shorter EFS and OS in total patients, and further subgroup analysis exhibited that AKIP1 high expression correlated with worse EFS and OS in intermediate-risk and poor-risk patients but not in better-risk patients. Besides, subsequent analysis revealed that AKIP1 high expression was an independent factor predicting unfavorable EFS and OS. Conclusion:A-kinase interacting protein 1 has the potential to be a novel marker for assisting AML management. K E Y W O R D S acute myeloid leukemia, A-kinase interacting protein 1, risk stratification, survival 1 | INTRODUC TI ON Acute myeloid leukemia (AML), an aggressive hematological malignancy, is characterized by abnormal cell proliferation and differentiation of the immature myeloid cells. 1,2 It accounts for 20% of all hematological malignancy related deaths, with a 5-year survival rate of 40% for younger patients (18-60 years) and 5-year survival rate of 10% for the elder patients (age above 60 years). 3-5 Despite there are potentially curative treatments for AML patients, including intensive chemotherapy and allogeneic stem cell transplantation, How to cite this article: Yan Y, Li X, Gao J. Identification of A-kinase-interacting protein 1 as a potential biomarker for risk and prognosis of acute myeloid leukemia. J Clin Lab Anal.

Prognostic significance of A-kinase interacting protein 1 expression in various cancers

“…Finally, 19 studies with 19 cohorts were included in this meta-analysis. The 19 cohorts, with a total of 3979 patients, were recruited throughout China, and patients were diagnosed with multiple types of cancer, that is tongue squamous cell carcinoma, [8] papillary thyroid carcinoma, [17] acute myeloid leukemia, [20,28] multiple myeloma, [19] prostate cancer, [25] cervical cancer, [27] clear cell renal cell carcinoma, [11] NSCLC, [16,21,26] gastric cancer, [15,18] hepatocellular carcinoma, [12,24,29] colorectal cancer, [22] breast cancer, [23] and epithelial ovarian cancer. [30] The sample sizes ranged from 50 to 490.…”

“…Moreover, AKIP1 is overexpressed in various cancers [12,15–23] . Thus, clinical studies have shown that AKIP1 overexpression is associated with poorer survival in a variety of cancers [12,15–21,23–30] . However, such conclusions remain controversial [8,17,22] .…”

“…[8,[14][15][16] Moreover, AKIP1 is overexpressed in various cancers. [12,[15][16][17][18][19][20][21][22][23] Thus, clinical studies have shown that AKIP1 overexpression is associated with poorer survival in a variety of cancers. [12,[15][16][17][18][19][20][21][23][24][25][26][27][28][29][30] However, such conclusions remain controversial.…”

“…[12,[15][16][17][18][19][20][21][22][23] Thus, clinical studies have shown that AKIP1 overexpression is associated with poorer survival in a variety of cancers. [12,[15][16][17][18][19][20][21][23][24][25][26][27][28][29][30] However, such conclusions remain controversial. [8,17,22] Therefore, we performed a meta-analysis to further explore the relationship of AKIP1 expression with prognosis and clinical characteristics in patients with cancer.…”

A-Kinase Interacting Protein 1 Promotes Cell Invasion and Stemness via Activating HIF-1α and β-Catenin Signaling Pathways in Gastric Cancer Under Hypoxia Condition

“…Most importantly, AKIP1 is also a promising oncology-related factor in recent studies. For instance, AKIP1 is upregulated in several cancers, and it also correlates with more deteriorative tumor features and survival profiles in these cancer patients, which suggests that it participates in the progression of many cancers (15)(16)(17)(18)(19). Above all, there is also correlation between AKIP1 and gastric cancer, which elucidates that it is involved in tumor progression through the modulation of Slug-induced epithelial-mesenchymal transition, which then enhances growth and metastasis of the tumor (20).…”